Lexicon entered into development agreement with Symphony Capital Partners to move Lexicon’s drug candidates - LX1671 in phase 2b clinical trials for treating cognitive disorders, LX1031 in phase 1b clinical trials for treating irritable bowel syndrome and LX1032 in preclinical stage for treating gastrointestinal disorders into advanced clinical development. The deal would worth up to US$60 M to Lexicon.